Amarin Corp Plc (AMRN)

[rfj1862]

So for the Q4 documents, it is unlikely that new data from REDUCE-IT will be in them, as they are likely already in press. What they often do when there is a paradigm-changing result is quickly issue an update to the guidelines which might be as short as 1-2 pages and could come as soon as Q1 of next year.

However, I feel like the REDUCE IT results are important enough that they could possibly delay the release of #1 and #2 to consider and include these data. I don't know--trials that are this significant don't happen that often to predict how they are going to react to it. Unknown territory.

If it does get a recommendation in the guidelines, it is possible that expanded coverage will follow from insurance companies regardless of when the formal indication is granted by the FDA. If this does happen, it likely wouldn't occur until after the full peer-review publication is available, which will presumably be before the end of the year.



4 major AHA/ACC Clinical Documents are in Progress, In order and approximate time of release:

1) Blood Cholesterol (Revision) expected Q4 2018

2) Use of Risk Assessment Tools to Guide Decision Making in Primary Prevention of Atherosclerotic Cardiovascular Disease (Companion Article to Blood Cholesterol Guidelines) expected Q4 2018

3) Recent Innovations, Modifications, and Evolution of ACC/AHA Clinical Practice Guidelines: An Update for our Consistituencies expected Q1 2019

4) Prevention of Cardiovascular Disease expected Q1 2019